Company Overview
GH Research PLC functions as a clinical-stage biopharmaceutical entity dedicated to developing therapeutic treatments for depression within the United States market. Operating within the broader healthcare sector and specifically the biotechnology industry, the company focuses on advancing early-stage drug candidates through clinical trials to address specific mental health conditions. The organization employs a workforce of 73 individuals and maintains a total market capitalization of $830.57M, reflecting its status as a mid-cap entity in the specialized biotech landscape. The absence of reported annual revenue figures, combined with a market cap exceeding $800 million, indicates that the company's valuation is driven primarily by the potential value of its pipeline assets and future commercial expectations rather than current cash generation or sales volume.
Financial Health
The company reports a net income of $-48,258,000 and an EBITDA of $-60,599,000 over the trailing twelve months, while revenue data is not currently available for disclosure. The substantial gap between reported revenue (which is effectively zero or unreported) and the significant net loss highlights a cost structure dominated by high research and development expenditures typical of clinical-stage development phases. Free cash flow stands at $-30,543,876, which signifies that the company is consuming cash reserves to fund its operations and clinical trials rather than generating liquidity from its business activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that indicates the company has not yet achieved profitability or generated sufficient sales volume to calculate meaningful margins. Despite these negative operating metrics, the balance sheet demonstrates significant liquidity with cash holdings of $280.71M against total debt of $512,000. This disparity between cash and debt results in a debt-to-equity ratio of 0.18, suggesting a conservative balance sheet structure that minimizes leverage risk. The current ratio is reported at 34.13, a metric that indicates an extremely strong ability to meet short-term obligations with current assets, providing ample financial flexibility despite the burn rate. Return on equity is -21.0% and return on assets is -15.9%, revealing that management is currently utilizing shareholder capital and assets to generate losses rather than returns, a common characteristic in pre-revenue biotechnology firms.
Valuation Assessment
The valuation metrics present a complex picture for the asset, with a P/E ratio (TTM) listed as N/A due to negative earnings, while the forward P/E is reported at -7.29. The negative forward P/E implies that analysts or the market does not expect positive earnings in the near term, reflecting the high uncertainty surrounding the successful completion of Phase 2b clinical trials for its lead product candidate. The price-to-book ratio stands at 2.97, indicating that the market values the company at nearly three times its book value, a premium often seen in biotech firms where intangible assets like intellectual property drive valuation rather than tangible net assets. Price-to-sales and EV/EBITDA ratios are either N/A or -9.08, suggesting that traditional revenue-based valuation models are not applicable given the lack of sales history, while the negative EV/EBITDA further underscores the heavy investment phase of the business. The stock has traded between a 52-week low of $7.98 and a 52-week high of $19.51, with the current market capitalization of $830.57M implying a significant portion of the equity value is priced above the recent high or near the mid-range depending on the specific share price at the time of calculation. The beta value is 1.00, which means the stock's price volatility generally moves in tandem with the broader market, lacking the typical high-beta volatility often associated with small-cap biotechnology companies.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, reflecting the fact that the company has not yet generated consistent commercial sales to establish a historical growth trajectory. The absence of revenue growth figures implies that the primary focus remains on clinical development milestones rather than scaling sales operations. Regarding income distribution, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This policy confirms that the company reinvests all available financial resources directly into research, development, and clinical trial expansion rather than distributing cash to shareholders. The overall growth and income profile is characterized by a reliance on future clinical success rather than current cash flow, with the $280.71M cash reserve serving as the primary fuel for continued operational growth and asset development.